February 5, 2026 – Irvine, Calif. and Istanbul, Turkiye – TAE Life Sciences US, LLC (“TAE Life Sciences”), a leader in accelerator-based boron neutron capture therapy (“BNCT”) for precision oncology, today announced the signing of an exclusive distribution agreement with Bozlu Holding A.S. (“Bozlu”), a diversified holding company headquartered in Istanbul, Turkiye, with more than 35 years of expertise in healthcare services. TAE Life Sciences is a minority-owned subsidiary of TAE Technologies, Inc (“TAE Technologies”). TAE Technologies is a leading fusion power company based in Southern California, USA.
BNCT is an advanced form of targeted radiation therapy that selectively destroys cancer cells while minimizing damage to surrounding healthy tissue. TAE Life Sciences’ accelerator-based BNCT platform and proprietary boron-10 drugs are designed to support hospital-based deployment.
Under the terms of the exclusive distribution agreement, Bozlu is appointed as the exclusive distributor of TAE Life Sciences’ Alphabeam™ BNCT platform and associated boron target drug candidates across a broad territory including Turkiye, Eastern Europe, and Central Asia, and will be responsible for marketing, promoting, distributing, and selling the BNCT system, as well as supporting the deployment of the technology at an initial clinical site to enable clinical trial research and regulatory approval in the region.
“This agreement represents a significant milestone in our global expansion strategy and underscores the growing international demand for BNCT as a highly targeted cancer treatment,” said Rob Hill, Chief Executive Officer of TAE Life Sciences. “Bozlu brings deep regional expertise, strong healthcare relationships, and the operational capabilities required to support both clinical research and commercialization. Together, we aim to accelerate patient access to BNCT in regions where advanced oncology solutions are urgently needed.”
Bozlu will work closely with TAE Life Sciences to engage leading hospitals, academic institutions, and regulatory authorities to establish clinical programs and support long-term adoption of BNCT technology.
“We are proud to partner with TAE Life Sciences to introduce this groundbreaking cancer treatment platform to Turkiye and neighboring markets,” said Ismail Dernek, Board Member of Bozlu. “BNCT represents a transformative opportunity for oncology care, and we believe this collaboration positions our region at the forefront of next-generation precision medicine.”
About TAE Life Sciences
TAE Life Sciences is pioneering next-generation BNCT with a pipeline of proprietary boron drugs and accelerator-based neutron systems, advancing precision radiation therapy and combination regimens to improve survival for patients with hard-to-treat cancers. TAE Life Sciences is a minority-owned subsidiary of TAE Technologies. TAE Technologies is a leading fusion power company based in Southern California, USA. For more information, visit www.taelifesciences.com.
About Bozlu
Bozlu is a Turkish conglomerate with diversified operations across healthcare, advanced technology services and industrial sectors. The Group is particularly active in oncological diagnosis and treatment, delivering high-technology solutions through its affiliated companies and contributing to broader healthcare innovation. Bozlu has a strong track record of executing complex, high-tech projects and supporting sustainable, regional growth initiatives. For more information, visit www.bozlu.com.
